{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:28:19Z","timestamp":1783164499243,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["Independent research collaboration"],"award-info":[{"award-number":["Independent research collaboration"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate treatment intervals at 12\/24 months following initiation of anti-VEGF therapy and to characterise the clinical profile of neovascular AMD (nAMD) patients achieving extended treatment intervals (\u226512 and \u226516 weeks).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>National, retrospective, real-world study using data from the validated web-based Fight Retinal Blindness (FRB!) registry. Treatment-naive nAMD eyes managed with approved first-generation intravitreal VEGF inhibitors (ranibizumab, aflibercept 2\u2009mg) and followed for at least 12 months were included. A subanalysis was conducted on eyes receiving a number of injections within range of a treat and extend (TAE) regimen at 12 and 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total number of 1278\/557 treatment-na\u00efve nAMD eyes within the TAE range category completed the required follow up at 12\/24 months. At 12 months, 39.3% of eyes remained on \u2264Q8W, 22.5% &gt;Q8W-\u2009&lt;\u2009Q12W, 29.1% \u2265Q12W-\u2009&lt;\u2009Q16 and 9.1% \u2265Q16W. At 24 months, the distribution was 35.4%, 17.6%, 28.3% and 18.7%, respectively. Mean VA change was not significantly different between groups at both 12 months (\u2264\u2009Q8W: +4.7, Q8-Q12: +3.5, Q12-Q16: +6.1, \u2265Q16W: +4.8 letters) and 24 months (\u2264Q8W: +5.8, Q8-Q12: +3.7, Q12-Q16: +4.1, \u2265Q16W: +3 letters). The percentage of visits with active lesions was similar across groups at both time points, indicating consistent disease control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite receiving a number of injections within a TAE range, a substantial proportion of eyes failed to achieve extended treatment intervals at 12 and 24 months (61.8% and 52.9%, respectively). These results underscore the significant unmet therapeutic need in the management of nAMD with currently approved first-generation anti-VEGF agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-03996-8","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:20:17Z","timestamp":1760620817000},"page":"3306-3313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment intervals with first-generation anti-vascular endothelial growth factor drugs: evaluating the unmet need in a real-world neovascular age-related macular degeneration national database"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-8143","authenticated-orcid":false,"given":"Javier","family":"Zarranz-Ventura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5255-8426","authenticated-orcid":false,"given":"Gonzaga","family":"Garay-Aramburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5312-8900","authenticated-orcid":false,"given":"Carolina","family":"Arruabarrena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Arn\u00e1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Garc\u00eda-Lunar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sararols-Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the FRB SPAIN study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Zarranz-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Martin-Pinardel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Figueras-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Moll-Udina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Izquierdo-Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Bernal-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Batll\u00e9-Ferrando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Marias-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socorro","family":"Alforja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo P.","family":"Casaroli-Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Ba\u00f1on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Rethati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Montejano-Milner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lia\u00f1o-Sanz D\u00edez de Ulzurrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Brosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00e1nchez-Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Garc\u00eda-Arum\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fern\u00e1ndez-Hortelano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Zarallo-Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Cobo-Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Lozano-Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Moreno-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Puzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Ruiz-Del-Tiempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Ruiz-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzaga","family":"Garay-Aramburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Arrazola Berrizbeitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Larrauri-Arana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"G\u00f3mez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rodr\u00edguez-Feijoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Diaz-de-Durana-Santa-Coloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maialen","family":"Aldazabal-Echeveste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuri\u00f1e","family":"del-Barrio-Lopez-de-Ipi\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Herrero-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximino Jos\u00e9","family":"Abraldes L\u00f3pez-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Lidia","family":"G\u00f3mez Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Rodr\u00edguez-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Fern\u00e1ndez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fern\u00e1ndez Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Gonz\u00e1lez Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muxima","family":"Acebes Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Aparicio Sanch\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cacelliere Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Belmonte Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta S.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Ciancas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Jos\u00e9","family":"Gonzalez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Cilveti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Miguel-Escuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M\u00aa","family":"Ruiz Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Vega-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Flores-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Salinas Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Lavid de los Mozos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Garc\u00eda-Layana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Saenz de Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fernandez-Robredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Recalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Juan","family":"Escobar-Barranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Fernandez-Bonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Pina-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Valldeperas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Broc-Iturralde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Vilaplana Mira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"G\u00f3mez S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Campos Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Arias-Barquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Cobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lorenzo Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen A.","family":"Rodr\u00edguez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Ascaso-Puyuelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Honrubia Grijalbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Boned Murillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"D\u00edaz Barreda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"P\u00e9rez Rivas\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Bakkali El Bakkali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Castro Casal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00f3bal","family":"Quintero Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rubio Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vel\u00e1zquez-Villoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Azrak Haskour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pi\u00f1ero S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gallego-Pinazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cholbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Dolz-Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Asencio Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e9lida","family":"Mu\u00f1oz Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J.","family":"Castill\u00f3n Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Catal\u00e1n Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Tena Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"de F\u00e1tima \u00c1lvarez Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purificaci\u00f3n","family":"Pi\u00f1as Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Mantrana Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saturnino","family":"Gismero-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Chinchurreta Capote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Gonz\u00e1lez Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Angel","family":"Moreno Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Carnota-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"M\u00e9ndez-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Torres-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rodr\u00edguez Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Ram\u00f3n","family":"Garc\u00eda-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Fonollosa Calduch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Galletero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Parrado-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Alarc\u00f3n-Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Diago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Hern\u00e1ndez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Pareja Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Angeles","family":"Espi\u00f1eira Peri\u00f1an","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Rodr\u00edguez-Maqueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sotomayor Toribio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Campo Gesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"3996_CR1","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"M Saylan","year":"2021","unstructured":"Bourne RRA SJ, Saylan M, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144\u2013e60.","journal-title":"Lancet Glob Health"},{"key":"3996_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik J-F, Mitchell P, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration \u2013 a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20:294.","journal-title":"BMC Ophthalmol"},{"key":"3996_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","volume":"153","author":"SB Bloch","year":"2012","unstructured":"Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209\u201313.","journal-title":"Am J Ophthalmol"},{"key":"3996_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ajo.2011.08.035","volume":"153","author":"A Skaat","year":"2012","unstructured":"Skaat A, Chetrit A, Belkin M, Kinori M, Kalter-Leibovici O. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2012;153:214\u201321.","journal-title":"Am J Ophthalmol"},{"key":"3996_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0974-9233.173133","volume":"23","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Aggarwal K, Gupta V. Management of neovascular age-related macular degeneration: a review on landmark randomized controlled trials. Middle East Afr J Ophthalmol. 2016;23:27\u201337.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"3996_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","volume":"125","author":"P Rao","year":"2018","unstructured":"Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, et al. Real-world vision in age-related macular degeneration patients treated with single anti\u2013VEGF drug type for 1 year in the IRIS Registry. Ophthalmology. 2018;125:522\u20138.","journal-title":"Ophthalmology"},{"key":"3996_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100:1623\u20138.","journal-title":"Br J Ophthalmol"},{"key":"3996_CR8","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1038\/s41433-023-02540-w","volume":"37","author":"A Loewenstein","year":"2023","unstructured":"Loewenstein A, Berger A, Daly A, Creuzot-Garcher C, Gale R, Ricci F, et al. Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries. Eye. 2023;37:3351\u20139.","journal-title":"Eye"},{"key":"3996_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/11206721211001716","volume":"32","author":"B Pina Mar\u00edn","year":"2022","unstructured":"Pina Mar\u00edn B, Gajate Paniagua NM, G\u00f3mez-Bald\u00f3 L, Gallego-Pinazo R. Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: results of the AMD-MANAGE study. Eur J Ophthalmol. 2022;32:385\u201394.","journal-title":"Eur J Ophthalmol"},{"key":"3996_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","volume":"34","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Walton R, Liong J, Arnold JJ, McAllister I, Morlet N, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project. Retina. 2014;34:188\u201395.","journal-title":"Retina"},{"key":"3996_CR11","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00417-020-05016-9","volume":"259","author":"M Figueras-Roca","year":"2021","unstructured":"Figueras-Roca M, Parrado-Carrillo A, Nguyen V, Casaroli-Marano RP, Moll-Udina A, Gillies MC, et al. Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry. Graefes Arch Clin Exp Ophthalmol. 2021;259:1463\u201370.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3996_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/ceo.13949","volume":"49","author":"V Nguyen","year":"2021","unstructured":"Nguyen V, Barthelmes D, Gillies MC. Neovascular age-related macular degeneration: a review of findings from the real-world Fight Retinal Blindness! registry. Clin Exp Ophthalmol. 2021;49:652\u201363.","journal-title":"Clin Exp Ophthalmol"},{"key":"3996_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/ceo.14054","volume":"50","author":"J Zarranz-Ventura","year":"2022","unstructured":"Zarranz-Ventura J, Parrado-Carrillo A, Nguyen V, Sararols L, Garay-Aramburu G, Puzo M, et al. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes. Clin Exp Ophthalmol. 2022;50:312\u201324.","journal-title":"Clin Exp Ophthalmol"},{"key":"3996_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21:133.","journal-title":"J Transl Med"},{"key":"3996_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"3996_CR16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141:834\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"3996_CR17","first-page":"2816","volume":"64","author":"RA Goldberg","year":"2023","unstructured":"Goldberg RA, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, et al. Faricimab reduces macular leakage vs aflibercept in patients with DME. Invest Ophthalmol Vis Sci. 2023;64:2816.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3996_CR18","first-page":"PB0039","volume":"64","author":"A Maunz","year":"2023","unstructured":"Maunz A, von, Schulthess E, Patel KM, Chakravarthy U, Bachmeier I, et al. Automated segmentation of hyperreflective foci in diabetic macular edema shows greater volume reduction by faricimab vs aflibercept in phase 3 YOSEMITE and RHINE. Invest Ophthalmol Vis Sci. 2023;64:PB0039\u2013PB.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3996_CR19","first-page":"2","volume":"9","author":"D Wong","year":"2025","unstructured":"Wong D, Chhabra R, Ruiz-Medrano J, Hamilton R. Improving clinic capacity with faricimab. EMJ Innov. 2025;9:2\u201311.","journal-title":"EMJ Innov"},{"key":"3996_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.oret.2023.10.022","volume":"8","author":"J Izquierdo-Serra","year":"2024","unstructured":"Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, et al. Macular neovascularization type influence on anti-VEGF intravitreal therapy outcomes in age-related macular degeneration. Ophthalmol Retin. 2024;8:350\u20139.","journal-title":"Ophthalmol Retin"},{"key":"3996_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bjo-2022-322297","volume":"108","author":"R Martin-Pinardel","year":"2024","unstructured":"Martin-Pinardel R, Izquierdo-Serra J, De Zanet S, Parrado-Carrillo A, Garay-Aramburu G, Puzo M, et al. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database. Br J Ophthalmol. 2024;108:253.","journal-title":"Br J Ophthalmol"},{"key":"3996_CR22","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1038\/s41433-024-03322-8","volume":"38","author":"M Puzo","year":"2024","unstructured":"Puzo M, Calvo-Perez P, Bartol-Puyal F, Sanchez-Monroy J, Martin-Pinardel R, Parrado-Carrillo A, et al. Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study. Eye. 2024;38:3450\u20138.","journal-title":"Eye"},{"key":"3996_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.04.012","volume":"168","author":"IA Rodrigues","year":"2016","unstructured":"Rodrigues IA, Sprinkhuizen SM, Barthelmes D, Blumenkranz M, Cheung G, Haller J, et al. Defining a minimum set of standardized patient-centered outcome measures for macular degeneration. Am J Ophthalmol. 2016;168:1\u201312.","journal-title":"Am J Ophthalmol"},{"key":"3996_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica. 2020;243:1\u20138.","journal-title":"Ophthalmologica"},{"key":"3996_CR25","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/eye.2016.90","volume":"30","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger AR, Cereda MG, Hykin P, et al. Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye. 2016;30:1063\u201371.","journal-title":"Eye"},{"key":"3996_CR26","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418\u201331.","journal-title":"Retina"},{"key":"3996_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41433-024-03370-0","volume":"39","author":"KYC Teo","year":"2025","unstructured":"Teo KYC, Eldem B, Joussen A, Koh A, Korobelnik JF, Li X, et al. Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration. Eye. 2025;39:860\u20139.","journal-title":"Eye"},{"key":"3996_CR28","first-page":"253","volume":"26","author":"S Kiss","year":"2020","unstructured":"Kiss S, Malangone-Monaco E, Wilson K, Varker H, Stetsovsky D, Smith D, et al. Real-world injection frequency and cost of ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration and diabetic macular edema. J Manag Care Spec Pharm. 2020;26:253\u201366.","journal-title":"J Manag Care Spec Pharm"},{"key":"3996_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","volume":"8","author":"C Boudousq","year":"2024","unstructured":"Boudousq C, Nguyen V, Hunt A, Gillies M, Zarranz-Ventura J, O\u2019Toole L, et al. European unmet needs in the management of neovascular age-related macular degeneration in daily practice: data from the Fight Retinal Blindness! Registry. Ophthalmol Retin. 2024;8:527\u201336.","journal-title":"Ophthalmol Retin"},{"key":"3996_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2019;137:372\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"3996_CR31","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/j.ophtha.2016.08.016","volume":"123","author":"MC Gillies","year":"2016","unstructured":"Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D. Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2016;123:2545\u201353.","journal-title":"Ophthalmology"},{"key":"3996_CR32","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/eye.2017.143","volume":"31","author":"A Lotery","year":"2017","unstructured":"Lotery A, Griner R, Ferreira A, Milnes F, Dugel P. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye. 2017;31:1697\u2013706.","journal-title":"Eye"},{"key":"3996_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2019.10.006","volume":"127","author":"S Bhandari","year":"2020","unstructured":"Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, et al. Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration: data from the Fight Retinal Blindness! Registry. Ophthalmology. 2020;127:369\u201376.","journal-title":"Ophthalmology"},{"key":"3996_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89\u201399.","journal-title":"Ophthalmology"},{"key":"3996_CR35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"3996_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retin Vitreous. 2024;10:5.","journal-title":"Int J Retin Vitreous"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03996-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03996-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03996-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:39:34Z","timestamp":1764599974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03996-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3996"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03996-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have completed and submitted the ICMJE disclosures form. JZV is a grant holder for Novartis, Bayer, Allergan\/Abbvie and Roche, and a consultant for Novartis, Bayer, Allergan\/Abbvie, Alcon, Alimera Sciences, Bausch and Lomb, Brill Pharma, DORC, Preceyes, Roche, Topcon, and Zeiss; is a member of the\n                      Eye\n                      editorial board. GG-A receives consulting fees from AJL S.A. and Ulma Medical Tech; payment of honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events of Roche and Ulma Medical Tech; and support for attending meetings and\/or travel of AbbVie, Novartis, and J&J. PA and PG-L are employees of Roche Spain. The rest of the authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}